PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19

P

Pardes Biosciences

Status and phase

Active, not recruiting
Phase 2

Conditions

COVID-19

Treatments

Drug: PBI-0451 (Pomotrelvir)
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05543707
PBI-0451-0002

Details and patient eligibility

About

This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19. PBI-0451(Pomotrelvir) is a new chemical entity and inhibitor of the main protease of coronaviruses, including the SARS-CoV-2 that causes COVID-19 disease. This study is designed to evaluate the antiviral activity, safety, and efficacy of orally administered PBI-0451(Pomotrelvir) compared with placebo.

Enrollment

210 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Can understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of any study procedures.
  • Onset of COVID-19 symptoms ≤ 5 days prior to randomization with a positive SARS-CoV-2 test ≤ 24 hours prior to randomization. Authorized NAAT or antigen tests that detect viral RNA or protein, respectively, are allowed.
  • Received primary vaccination series as defined by Centers for Disease Control and Prevention (CDC). Subjects should be advised during informed consent that alternate therapies may be available outside of study participation.
  • ≥ 2 symptoms of acute COVID-19 infection as determined by the investigator from the symptoms listed on the COVID-19 symptoms questionnaire present at randomization
  • Male and nonpregnant, nonlactating female subjects 18 to < 65 years of age. Females must have a negative serum or urine pregnancy test at screening and prior to the first dose of study drug unless permanently sterile or in a postmenopausal state (see Appendix 3).
  • Male and female subjects and/or their heterosexual partners must either be of nonchildbearing potential or must use effective contraception from screening through 90 days after the last dose of study drug (see Appendix 3)
  • Female subjects must refrain from egg donation and in vitro fertilization during treatment and for ≥ 28 days after the last dose of study drug
  • Male subjects must refrain from sperm donation from screening through 90 days after the last dose of study drug
  • Normal 12-lead electrocardiogram (ECG) evaluation without clinically significant abnormalities
  • Able and willing to comply with all study requirements

Exclusion criteria

  • Considered at high-risk of developing severe illness from COVID-19 defined as ≥ 1 CDC underlying medical condition associated with an increased risk of developing severe illness from COVID-19 (see Appendix 5)
  • Unvaccinated against SARS-CoV-2 (defined as having not completed a primary vaccination series)
  • Any SARS-CoV-2 vaccination within 3 month prior to randomization or anticipated to receive a SARS-CoV-2 vaccination (including a booster) during the 28-day study period
  • Currently hospitalized or expected to require hospitalization for COVID-19 within 48 hours of randomization
  • Currently being treated or expected to be treated for COVID-19 with monoclonal antibodies, convalescent serum, or direct-acting antiviral agents (all potential subjects should be informed of evolving treatment options during informed consent that alternate therapies may or may not be available to them outside of study participation)
  • Any clinical condition or laboratory result considered by the investigator to indicate any unstable or poorly controlled underlying clinically significant medical condition(s), active disseminated infection (other than SARS-CoV-2), or other medical condition that could represent a risk to the subject, including increasing the likelihood of a safety event, affect subject compliance, or affect efficacy and/or safety data collected during the 28-day study period
  • Known active liver disease, including nonalcoholic steatohepatitis/nonalcoholic fatty liver disease, chronic or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, primary biliary cirrhosis, Child-Pugh Class B or C, chronic alcoholic liver disease, or acute liver failure
  • Receiving dialysis or having known severe renal impairment (chronic kidney disease, Stage 4 or above)
  • Unable or unwilling to comply with the protocol procedures
  • Participating in another interventional study with an investigational compound or device, including those for COVID-19
  • Known prior participation in this study or another study involving PBI-0451(Pomotrelvir)
  • Females who are pregnant or breastfeeding
  • Oxygen saturation of < 94% on room air

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

210 participants in 2 patient groups, including a placebo group

PBI-0451 (Pomotrelvir)
Experimental group
Description:
PBI-0451(Pomotrelvir): 2 x 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
Treatment:
Drug: PBI-0451 (Pomotrelvir)
Placebo
Placebo Comparator group
Description:
PBI-0451(Pomotrelvir): 2 x placebo to match PBI-0451(Pomotrelvir) tablets administered orally twice daily (BID) with food for 5 days (10 total doses)
Treatment:
Drug: Placebo

Trial contacts and locations

54

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems